I see that investors in Pfizer are stunned by a fall of more than £15 billion in the value of the drug company after trials of the cholesterol-lowering drug Torcetrapib were stopped.
In clinical trials there were 60 per cent more deaths in the group taking the animal-tested drug than in the group given a placebo. Perhaps investors should support our campaign.
Pat Rattigan
Director, British Anti-Vivisection Association